NCT07122180Enrolling by invitation
Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 22 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Post market Clinical follow-up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in patients with Type 1 and Type 2 Diabetes Mellitus
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 72 (estimated)
- First submitted
- 7 Aug 2025
- Start date
- 4 Jun 2025
- Primary completion date
- 17 Sept 2025
- Lead sponsor
- MDCECRO LLC
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07122180
What you commit to
- Study type: Observational
- Planned participants: 72
- From 4 Jun 2025 to the primary completion date, 17 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1.Those who have broken, scarred, red, swollen, or infected skin on the upper arms or abdomen.
- 2.Those who are allergic to alcohol disinfectants or medical adhesive tapes. 3.Those who have hematologic diseases that affect coagulation function or have been diagnosed with a bleeding tendency.
- 4.Those who have anemia or abnormal hematocrit. 5.Pregnant and lactating women. 6.Psychiatric abnormalities, cognitive and communication disorders, or highly stressed and uncooperative.
- 7.Those with subcutaneous edema at the wearing site. 8. Those who plan to undergo magnetic resonance imaging (MRI), computed tomography (CT), or X-ray examination within 14 days of wearing.
- 9\. Those who have participated in clinical trials of drugs or devices within 1 month.
- 10.Those who are considered by the investigator to be inappropriate to participate in this PMCF study.
Who the study is looking for
- 1.Patients diagnosed with type 1 or 2 diabetes mellitus. 2.People aged 18 years or older, regardless of gender. 3.Those who sign informed consent to participate in this study voluntarily. 4.The patient had good compliance and could complete this whole clinical investigation.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Paula Stradiņa Klīniskā Universitātes Slimnīca Coordinator of this site? Confirm its status | Riga | Latvia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.